Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Open Access
- 1 July 2006
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 10 (1), 39-50
- https://doi.org/10.1016/j.ccr.2006.05.024
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2Developmental Biology, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-α-Converting EnzymeMolecular and Cellular Neuroscience, 2000
- An Essential Role for Ectodomain Shedding in Mammalian DevelopmentScience, 1998
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Autocrine and paracrine growth regulation of breast cancer: Clinical implicationsBreast Cancer Research and Treatment, 1990
- Autocrine Secretion and Malignant Transformation of CellsNew England Journal of Medicine, 1980